CHD/Prevention News

Shortages of tirzepatide, a GIP/GLP-1 dual agonist approved for the treatment of type 2 diabetes and obesity, have been resolved, the FDA announced.

The American Heart Association Scientific Sessions will be held in-person only in Chicago from Nov. 16 to 18 and will feature eight late-breaking science sessions during the 3-day meeting.

SAN DIEGO — Managing systemic inflammation is critical to reducing cardiovascular and pulmonary outcomes in patients with rheumatoid arthritis, according to a presenter at the 2024 Congress of Clinical Rheumatology West.

In a phase 2a trial of patients with obesity-related HF with preserved ejection fraction, a novel controlled metabolic accelerator was associated with weight loss at 3 months compared with placebo.

Decreases in body weight and HbA1c induced by GLP-1 receptor agonists and other diabetes drugs can reduce the risk for cardiometabolic complications for adults newly diagnosed with type 2 diabetes, researchers reported.

In patients with persistent chylomicronemia, plozasiran, a small interfering RNA therapy, was associated with lower triglyceride levels and reduced risk for pancreatitis, researchers reported at the European Society of Cardiology Congress.

Women with obesity and atherosclerotic CVD without diabetes experience fewer CV events vs. men enrolled in the SELECT trial; however, semaglutide was linked to significant reductions in CV events regardless of sex, a speaker reported.

In this episode, host Hansa Bhargava, MD, discusses physician burnout, mindfulness and the effects of stress on heart health with Jonathan Fisher, MD, FACC.

Optimal heart health during the first trimester of pregnancy was associated with lower risk for hypertensive disorders of pregnancy, a speaker reported.

Hospital admissions for heart attack increased after exposure to lower air temperature and cold spells, researchers reported at the European Society of Cardiology Congress.